[Leiomyosarcoma of the inferior vena cava].

Leiomyosarcoma of vena cava are rare tumors. They occur preferentially in the inferior vena cava. They affect preferentially women and the median age of incidence is on fifth decade.

[Advances concerning aliskiren, direct renin inhibitor and aliskiren-hydrochlorothiazide].

Aliskiren (Rasilez), a direct renin inhibitor, is currently indicated for the treatment of essential hypertension, as monotherapy or in combination, especially with hydrochlorothiazide (Rasilez HCT). It may also be use to obtain a more complete blockade of the renin-angiotensin-aldosterone system (RAAS) when it is associated with an angiotensin converting enzyme inhibitor (ACEI) (or an AT1 angiotensin receptor antagonist) (ARA). There is some room for agents that may be more efficacious in reducing the progression of diabetic nephropathy than ACEI or ARA.

Acute and chronic effect of molsidomine extended release on exercise capacity in patients with stable angina, a double-blind cross-over clinical trial versus placebo.

A double-blind, placebo-controlled, cross-over study was performed in 50 patients with ischemic heart disease and stable angina to determine the duration of efficacy of 8 mg molsidomine in extended-release form. Exercise testing was performed at baseline and 2, 4, 6, 8, and 10 h after intake of either the medication or the placebo. Total duration of exercise (in minutes) and total work performance (workload x min) was significantly improved in the molsidomine retard group, not only compared with baseline but also with placebo for all time-points.

Placebo-controlled comparison of spirapril at 6, 12 and 24 mg/day in mild to severe essential hypertension.

In a double-blind, parallel-group study, 260 patients with mild to severe essential hypertension were randomized to treatment with placebo or spirapril at 6, 12 or 24 mg once daily for 6 weeks. When blood pressures were measured at the end of the dosing interval (trough), all spirapril regimens had produced similar reductions in sitting systolic and diastolic blood pressures (siSBP/siDBP) which were significantly greater than those observed in placebo-treated patients. There were no relevant changes in resting heart rate in any of the study groups.

Effect of bopindolol on the circadian blood pressure profile in essential hypertension.

The effect of bopindolol on circadian blood pressure and heart rate profile was evaluated by means of an automatic recording technique (Pressurometer II). Blood pressure and heart rate was measured every 15 min for 24 h in 11 ambulant hypertensive patients. Recordings were made after 2 weeks on placebo then after treatment for 4 and 8 weeks with single daily doses of 0.